Barak Ben Arye - 30 Jun 2026 Form 4 Insider Report for NovoCure Ltd (NVCR)

Reporting relationship: General Counsel
Issuer ticker: NVCR
Reported as of: 30 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Jul 2026, 16:30:27 UTC
Prior SEC filing: 05 Mar 2026
Source filing: View source filing
Reporting owner signature: Steven Robbins, as attorney in fact for Ben Arye, Barak

Key filing fact

Barak Ben Arye filed Form 4 for NovoCure Ltd (NVCR) on 01 Jul 2026.

Key facts

This page summarizes Barak Ben Arye's Form 4 filing for NovoCure Ltd (NVCR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Jul 2026, 16:30.

Change

Previous filing in this sequence was filed on 05 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001917165 Primary reporting owner

Ben Arye Barak

Relationship: General Counsel
Address: C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE
Signature: Steven Robbins, as attorney in fact for Ben Arye, Barak
Signature date: 01 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NVCR transaction

Ordinary Shares

Award

Transaction value
Shares: +1,299
Change %: +0.54%
Price: $11.15^*
Shares after: 243,752
Date: 30 Jun 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).

Footnote F2

In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026.